# Comanche Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/comanche-biopharma

- Industry: Biotechnology
- Headquarters: Concord, US
- Website: www.comanchebiopharma.com/
- Total disclosed funding: $38M
- Latest round: Series B (Dec 14, 2023)
- Investors on record: 6

## About

Founded in 2020 by Mike Young and Thomas Scott Johnson, and based in Massachusetts, US, Comanche Biopharma Corp. operates as a biopharmaceutical company that develops siRNA therapy for the treatment of preeclampsia. In December 2023, Comanche Biopharma Corp. raised USD 37.50 million in Series B funding co-led by New Enterprise Associates and Atlas Venture, with participation from GV (Google Ventures), F-Prime Capital, Lilly Asia Ventures (LAV), and Longview Healthcare Ventures.

Comanche Biopharma specializes in developing an investigational siRNA medicine specifically aimed at addressing preterm preeclampsia, a severe pregnancy complication that poses significant risks to both mothers and infants. This therapeutic approach is designed to provide evidence-based solutions that cater to the urgent need for treatments in high-risk pregnancies. The company's primary target market includes healthcare providers, hospitals, and maternal-fetal medicine specialists who require reliable interventions to manage complications associated with pregnancy. 

 The company intends to use the December 2023 funding to initiate a clinical study of CBP-4888.

## Funding rounds

- Series B, Dec 14, 2023, $38M — Atlas Venture, New Enterprise Associates, F-Prime Capital, Lilly Asia Ventures, GV, Longview Ventures

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series B
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B
- Longview Ventures — Series B